完全展开的冠状动脉支架的管理迁移到左侧主动脉
Enes Çelik1, Neryan Özgül Özden2, Gürkan İmre1
1Department of Cardiology, Bilecik Şeyh Edebali University, Faculty of Medicine, Bilecik, Türkiye.
概括
在穿皮冠状动脉干预 (PCI) 期间部署后冠状动脉支架迁移的罕见病例得到了成功管理. 一种新的气球 anchoring技术允许提取和固定,防止严重的并发症.
科学领域:
- 干预心脏病学 干预心脏病学
- 心血管外科心血管外科
背景情况:
- 支架迁移是穿皮冠状动脉干预 (PCI) 期间罕见但严重的并发症.
- 完全部署后的迁移是非常罕见的,这给管理带来了重大挑战.
研究的目的:
- 在PCI后报告一种独特的药物排泄支架迁移到左主冠状动脉 (LMCA) 的病例.
- 用一种新的技术来描述这种罕见并发症的成功管理.
主要方法:
- 一名39岁的男性患有非ST升高心肌梗塞 (NSTEMI) 接受了左环动脉 (LCx) 的PCI.
- 在支架植入后,支架近距离迁移到LMCA.
- 采用气球定机动来提取和重新放置迁移的支架,然后用额外的支架固定.
主要成果:
- 最初试图捕捉迁移的支架是没有成功的.
- 气球定技术成功地将支架重新放置到辐射动脉上.
- 迁移的支架被额外的支架固定起来,LCx的PCI完成了有利的血管学结果.
结论:
- 这一案例凸显了适当的支架选择的重要性,以及对诸如血管等倾向因素的认识.
- 熟悉先进的检索和管理技术对于处理罕见的支架迁移并发症至关重要.
- 气球定机动在管理这一具有挑战性的临床场景方面被证明是有效的.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
208
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
208
Cardiac Catheterization III: Left Heart Catheterization
549
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
549
Acute Coronary Syndrome IV: Interprofessional Care
211
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
211
Acute Coronary Syndrome I: Introduction
772
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
772
Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Mitral Stenosis III: Medical Management
237
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
237


